2026 · 2nd Quarter (Apr 1 - June 30)

TRANSPARENCY-RX CORP.

Filed by ARENTFOX SCHIFF LLP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Termination
Posted: Oct 19, 2026
Income: $20,000.00
Expenses: Not reported
Registrant: ARENTFOX SCHIFF LLP
Client: TRANSPARENCY-RX CORP.
Filing UUID: d0b4d11c-7e8c-4851-a8a3-fd6a0df1995a
Termination date: Jun 14, 2026

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Pharmacy Benefit Manager reform Transparency in prescription drug markets Prescription drug prices H.R.7148 (Consolidated Appropriations Act, 2026), regarding Pharmacy Benefit Manager reform, transparency in prescription drug markets, and prescription drug prices H.R. 6609 and H.R. 6610 (Pharmacists Fight Back Act), generally H.R. 5582 and S. 2355 (Patients Deserve Price Tags Act), generally

Literal federal measure citations: H.R.7148, H.R. 6609, H.R. 6610, H.R. 5582, S. 2355

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.